Single-agent Rituximab as Maintenance Treatment Versus Observation After Combined Induction Immunochemotherapy With Fludarabine, Cyclophosphamide and Rituximab in Patients Older Than 65 Years With Previously Untreated Chronic Lymphocytic Leukemia: a Phase III Trial of FILO
Phase of Trial: Phase III
Latest Information Update: 03 Aug 2017
At a glance
- Drugs Rituximab (Primary) ; Cyclophosphamide; Fludarabine
- Indications Chronic lymphocytic leukaemia
- Focus Therapeutic Use
- 31 Aug 2018 Biomarkers information updated
- 16 Oct 2015 Status changed from recruiting to completed as reported by ClinicalTrials.gov record.
- 25 Feb 2013 Planned number of patients changed from 304 to 542 as reported by ClinicalTrials.gov.